More Shades of 2000

 | Apr 10, 2014 | 6:20 PM EDT  | Comments
  • Comment
  • Print Print
  • Print

As I reviewed biotechs and techs to identify common weaknesses tonight, I was struck by the one thing I was most afraid to see: massive insider selling by people at every level of the companies. It's endemic.

And that's the 2000 thing all over again. It's gotten even more eerie when you consider that right at about this time in 2000, we started having nasty swings like we saw yesterday and today. At that time, the whole Nasdaq was overvalued, so there was a long way to fall, especially because we had come a long way in a short time.

This time, we've come a long way in a long time, and many very solid companies have been responsible for that run. But we all know that the last leg of this run saw a level of supply that has overwhelmed momentum funds and levered hedge funds alike.

Now keep in mind that we are only 3.5% from the highs, and we have seen lower levels just this year, but today the pain spilled over badly to the financials. In fact, that was the really defining element of the session, as interest rates plummeted when they should have gone up very big.

I am a broken record about the issuance. It has to stop for this market to be anything but "sell the rips and short 'em," which is now the prevailing wisdom.

But we have artificial help in both directions. As Herb Greenberg writes, the heavily shorted stocks were a huge part of the run-up. Now the insider selling at many of those same shorted stocks is breaking the dam.

The bulls must hope the busted Ally Financial (ALLY) was a wake-up call that there could be a better time to sell than now and that the market won't bear up any longer. The bulls must hope, also, that the Nasdaq hits a level where hedge funds and momentum funds can't or won't or don't have to sell.

Otherwise, the 2000 comparisons will keep occurring, and the selling will get heavier, not lighter, as we go along. 

Columnist Conversations

Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Before: Transparency is...
EA reported June revenue of $775 mlm vs. $714 est. much better than expected. EPS of $0.19 blew away the St es...
BIDU still has some higher targets, but it's a good idea to TRAIL UP stops when you EXTEND the prior swings. ...
Shares of Knight Transportation (KNX) are breaking out of a rising triangle pattern to all-time highs, ahead o...

BEST IDEAS

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.